Free Trial

Cardiff Oncology Q2 2023 Earnings Report

Cardiff Oncology logo
$3.06 -0.08 (-2.55%)
As of 04/1/2025 04:00 PM Eastern

Cardiff Oncology EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Cardiff Oncology Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
$0.08 million
Beat/Miss
Beat by +$30.00 thousand
YoY Revenue Growth
N/A

Cardiff Oncology Announcement Details

Quarter
Q2 2023
Time
N/A
Remove Ads

Cardiff Oncology Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Cardiff Oncology price target raised to $17 from $13 at H.C. Wainwright
Piper Sandler Reaffirms Their Buy Rating on Cardiff Oncology (CRDF)
See More Cardiff Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email.

About Cardiff Oncology

Cardiff Oncology (NASDAQ:CRDF), a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

View Cardiff Oncology Profile

More Earnings Resources from MarketBeat